Article

Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells

2022-09-19

Abstract excerpt

Telomere maintenance mechanisms are a hallmark of cancer and are required to enable the replicative immortality of malignant cells. While most cancers activate the enzyme telomerase for telomere maintenance, a subset of cancers (~10-15%) use telomerase-independent mechanisms termed alternative lengthening of telomeres (ALT). ALT is characterized by elevated replication stress at telomeres, telomere synthesis via h...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f3cff2b1-918f-54bf-8b57-a2674266e509
DOI: 10.1101/2022.09.19.507319

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cellsDOI 10.1101/2022.09.19.507319Read

Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.Semantic proximity Read

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific mannerSemantic proximity Read

ALTering cancer by triggering telomere replication stress through the stabilization of promoter G-quadruplex in SMARCAL1Semantic proximity Read

Alternative lengthening of telomeres: mechanism and the pathogenesis of cancerSemantic proximity Read

SMARCAL1 is a candidate therapeutic target for ALT-positive tumorsSemantic proximity Read

SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.Semantic proximity Read

Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.Semantic proximity Read

Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.Semantic proximity Read

Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooksSemantic proximity Read

Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomasSemantic proximity Read

Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres PathwaySemantic proximity Read

ALT in Pediatric High-Grade Gliomas Can Occur without ATRX Mutation and is Enriched in Patients with Pathogenic Germline MMR VariantsSemantic proximity Read

Cancer-associated <i>SMARCAL1</i> loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells

Abstract excerpt

Topics

Identifiers and source

Related research